12:00 AM
Feb 06, 2012
 |  BioCentury  |  Emerging Company Profile

Nanocytomics: Seeing tiny changes

Nanocytomics using imaging to non-invasively identify risk of cancer

Lung cancer is one of the deadliest cancers in the U.S. in part because it is often diagnosed too late to be treatable. Nanocytomics LLC thinks its high-resolution imaging technology can cheaply and non-invasively identify patients at high risk of developing lung and other cancers. The company hopes its tests will become standard of care in asymptomatic subjects, akin to Pap smears for cervical cancer.

The company uses partial wave spectroscopy (PWS) microscopy, an optical technique developed by co-founder and CEO Vadim Backman at Northwestern University, where he is a professor in the department of biomedical engineering.

PWS detects changes in cell morphology as small as 10 nm - a 20-fold better resolution than conventional light microscopy. This increased resolution enables PWS to detect changes indicative of early stages of carcinogenesis in cells that otherwise appear normal.

Nanocytomics has an exclusive, worldwide license to PWS technology from Northwestern, which has an undisclosed stake in the company and is eligible for royalties.

Nanocytomics plans to use the technology for non-invasive screening....

Read the full 839 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >